Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
about
Use of Animal Models in Understanding Cancer-induced Bone PainPotential prognostic, diagnostic and therapeutic markers for human gastric cancerCCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone lossHistotripsy focal ablation of implanted prostate tumor in an ACE-1 canine cancer model.Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinomaMusculoskeletal molecular imaging: a comprehensive overview.Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastasesBiochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cellsThe histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone lossEffect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice.Development of a brain metastatic canine prostate cancer cell line.Characterization of bone resorption in novel in vitro and in vivo models of oral squamous cell carcinoma.Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancerThe role of Dickkopf-1 in bone development, homeostasis, and diseaseCombined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton.Implication of platelet-derived growth factor receptor alpha in prostate cancer skeletal metastasisA human GRPr-transfected Ace-1 canine prostate cancer model in mice.Nanoparticulate paclitaxel demonstrates antitumor activity in PC3 and Ace-1 aggressive prostate cancer cell lines.A novel canine model for prostate cancer.Local treatment of mixed osteolytic/osteoblastic spinal metastases: is photodynamic therapy effective?Evaluating the effects of mixed osteolytic/osteoblastic metastasis on vertebral bone quality in a new rat model.Animal Models of Bone Metastasis.
P2860
Q26785501-6F3DA940-30F3-435D-85F5-443CBF33F9B3Q26866200-A2F4965C-2D48-4910-93A0-A802E598C9C8Q27348129-F685C7F8-D905-49B3-A27C-F6B45EE30B61Q28546055-2EEDB92A-FB01-4B68-9D59-B445A9237D0BQ30420699-E83498E7-A00F-4F72-BFB3-7CAE4D730B2EQ34267831-BA630B9D-1A72-43F2-9112-1F15489FA983Q34473019-C881F8C9-EC41-4A14-B8ED-2D81ADD9ADA5Q34511164-9806EFC3-07CA-4F08-B1C3-D215460116D8Q34541354-DADC993D-2E12-4DB1-95EA-12A4B6A059A3Q34686787-BCA5B5C3-17C7-43E8-9658-5377200B5185Q34829069-C4FCEF92-278E-4855-A2A2-C64DDB8B31DFQ35116018-21B6D419-9E97-4C04-8A69-7091B202031CQ35954707-A032512B-FE1A-40AB-BD47-9086CCD5611BQ35985440-8F01934F-D2F0-4A93-B338-E254E6494B70Q37066218-83B8A971-0185-4E7D-9917-CDDA78BC22DBQ37117104-2DB72A77-A54C-497C-9FBF-BA0EA2307A4FQ37418939-71A5725D-9F57-4B68-9B43-4BBCA2B962F3Q37924342-2F828696-DC53-4479-B0F2-3D8C4712759AQ38789134-5B3CC368-9A7D-4ED2-86C4-3026D9732808Q39096986-6DE35B37-51B7-44FC-9368-6D0B8F578F48Q39207608-A2C3589B-0261-49B8-ADEB-FE8987F245DDQ39447169-FB918228-244C-4B7D-8553-7E2F1D1E7593Q39453306-98433D97-7704-43D1-83D5-87B7716D87DCQ53489280-D502BA6A-45D0-43C0-9CCF-E62685C038D4
P2860
Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Zoledronic acid decreased oste ...... ancer with mixed bone lesions.
@ast
Zoledronic acid decreased oste ...... ancer with mixed bone lesions.
@en
type
label
Zoledronic acid decreased oste ...... ancer with mixed bone lesions.
@ast
Zoledronic acid decreased oste ...... ancer with mixed bone lesions.
@en
prefLabel
Zoledronic acid decreased oste ...... ancer with mixed bone lesions.
@ast
Zoledronic acid decreased oste ...... ancer with mixed bone lesions.
@en
P2093
P2860
P356
P1433
P1476
Zoledronic acid decreased oste ...... cancer with mixed bone lesions
@en
P2093
Chelsea K Martin
Jillian L Werbeck
Joseph J Pinzone
Murali V P Nadella
Nanda K Thudi
Soledad A Fernandez
P2860
P304
P356
10.1002/PROS.20776
P577
2008-07-01T00:00:00Z